đš Major RNA technology deal for $NOVN.NE
Novartis has entered into an agreement with China-based Abogen in the field of RNA-encoded therapeutics.
đ° $575 million upfront payment
đ” Up to $7.2 billion in milestone payments if all options are exercised
â Plus, rights to royalties on future product sales
𧏠The deal centers on ABO2203.
ABO2203 aims to produce a CD19ĂCD3 T-cell engager within the body using mRNA.
đŻ One of the key initial objectives is to reprogram or reset B cells in autoimmune diseases.
The crucial point: Novartis is not just acquiring a single drug; it is also securing an option on Abogenâs RNA platform for next-generation therapies.
Novartis has entered into an agreement with China-based Abogen in the field of RNA-encoded therapeutics.
đ° $575 million upfront payment
đ” Up to $7.2 billion in milestone payments if all options are exercised
â Plus, rights to royalties on future product sales
𧏠The deal centers on ABO2203.
ABO2203 aims to produce a CD19ĂCD3 T-cell engager within the body using mRNA.
đŻ One of the key initial objectives is to reprogram or reset B cells in autoimmune diseases.
The crucial point: Novartis is not just acquiring a single drug; it is also securing an option on Abogenâs RNA platform for next-generation therapies.